Value proposition

What is a value proposition?

A value proposition is a clear, evidence-based summary of a product’s core clinical, economic and humanistic advantages. It explains which unmet need the therapy addresses, how it improves outcomes for patients and health systems, and why its price is justified relative to relevant alternatives.

The core proposition should be consistent, but its emphasis and language are tailored to the decisions of different stakeholders, including clinicians, payers and health technology assessment bodies. It gives teams a common account of where the product creates value, for whom and on what evidence.

Why does a value proposition matter in market access?

The value proposition underpins market access, pricing, reimbursement and stakeholder engagement strategies. It helps teams explain why a medicine should be funded, used or preferred within a defined patient population and treatment pathway.

It also aligns medical, HEOR, regulatory and commercial teams around the outcomes and differentiators that matter. When developed early, it can expose evidence gaps, guide evidence generation and support launch planning. If it is vague, inconsistent or unsupported, different teams may make conflicting claims or focus on benefits that decision-makers do not consider relevant.

How is a pharmaceutical value proposition developed in practice?

Development starts with the decision context rather than a list of product features. Teams typically:

• Define the target population, treatment setting and place in the pathway.
• Describe the current standard of care, its limitations and the remaining unmet need.
• Identify relevant comparators, including non-drug care where appropriate.
• Select clinical, economic and humanistic outcomes that matter to each stakeholder.
• Assess the strength, relevance and limitations of the available evidence.
• Translate product attributes into benefits for patients, clinicians, payers and health systems.
• Test whether the proposed differentiation is credible, specific and consistent with the evidence.

The final wording should remain traceable to source data. Assumptions and evidence gaps should be recorded rather than hidden, particularly where economic value depends on modelling or anticipated changes in service use.

How should a value proposition be tailored for different stakeholders?

Tailoring changes the emphasis, not the underlying evidence. Clinicians may prioritise efficacy, safety, patient selection and practical use. Payers may focus on comparative outcomes, eligible population, budget impact and uncertainty. Patients may place greater weight on symptoms, functioning, treatment burden and quality of life.

For health technology assessment, the proposition must fit the relevant population, intervention, comparator and outcomes, and should acknowledge uncertainty. Local adaptation may also be needed because treatment pathways, comparators, costs and reimbursement criteria vary between markets. Tailoring should never turn an unsupported assumption into a claim.

Who owns the value proposition, and what does good governance look like?

Ownership is usually cross-functional. Market access often coordinates development, while medical, HEOR, regulatory, commercial and clinical colleagues contribute evidence and test the wording. Local teams assess whether the global proposition reflects their decision environment and identify where adaptation is required.

Good governance includes an agreed evidence base, clear claim ownership, version control and a process for review when new data, indications, competitors or payer requirements emerge. Common failures include drafting the proposition too late, treating it as a slogan, relying on efficacy without comparative or economic context, and using one stakeholder narrative unchanged for every audience.

How does a value proposition differ from the documents and strategies around it?

A value proposition is the concise strategic argument for a product’s value. A global value dossier is the more detailed evidence resource that substantiates that argument and supports local submissions and adaptation. Pricing and reimbursement strategy uses the proposition to pursue an access objective, but also considers affordability, negotiation, policy and market-specific rules.

It is also broader than a product claim or message. Claims are individual, evidence-supported statements; messages translate selected elements for a particular audience. The value proposition connects those statements into a coherent account of unmet need, differentiated outcomes and economic and humanistic value.